Bonner, William

Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas

Kummar, S., Chen, A., Ji, J., Zhang, Y., Reid, J. M., Ames, M., Jia, L., Weil, M., Speranza, G., Murgo, A. J., et al. (2011) · Cancer Research

PARP inhibition in cancer therapyCancer therapeutics and mechanisms

Cited by 259

Mito-Tempol and Dexrazoxane Exhibit Cardioprotective and Chemotherapeutic Effects through Specific Protein Oxidation and Autophagy in a Syngeneic Breast Tumor Preclinical Model

Dickey, J. S., Gonzalez, Y., Aryal, B., Mog, S., Nakamura, A. J., Redon, C. E., Baxa, U., Rosen, E., Cheng, G., Zielonka, J., et al. (2013) · PLoS ONE

Chemotherapy-induced cardiotoxicity and mitigationBioactive Compounds and Antitumor Agents

Cited by 60